Recent Finacing
Recent Raise
Earli operates a synthetic biopsy platform using programmable genetic constructs to reprogram tumors to express detectable synthetic biomarkers for PET and blood-based early cancer detection and localization.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors
See the team members at Earli.
